Bank of Nova Scotia Has $24.10 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bank of Nova Scotia increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) by 176.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 40,764 shares of the biopharmaceutical company’s stock after buying an additional 25,994 shares during the period. Bank of Nova Scotia’s holdings in Regeneron Pharmaceuticals were worth $24,097,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Core Alternative Capital increased its holdings in Regeneron Pharmaceuticals by 800.0% during the first quarter. Core Alternative Capital now owns 36 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 32 shares during the last quarter. Addison Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 220.0% in the first quarter. Addison Advisors LLC now owns 48 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 33 shares during the last quarter. ACG Wealth acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at $30,000. Whittier Trust Co. of Nevada Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 83.3% in the first quarter. Whittier Trust Co. of Nevada Inc. now owns 55 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 25 shares during the last quarter. Finally, Bellevue Asset Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 96.6% in the first quarter. Bellevue Asset Management LLC now owns 57 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 28 shares during the last quarter. 84.92% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Marc Tessier-Lavigne sold 3,428 shares of the business’s stock in a transaction dated Friday, September 30th. The stock was sold at an average price of $698.00, for a total transaction of $2,392,744.00. Following the completion of the transaction, the director now owns 2,269 shares of the company’s stock, valued at $1,583,762. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Regeneron Pharmaceuticals news, Director Marc Tessier-Lavigne sold 3,428 shares of the business’s stock in a transaction dated Friday, September 30th. The stock was sold at an average price of $698.00, for a total transaction of $2,392,744.00. Following the completion of the transaction, the director now owns 2,269 shares of the company’s stock, valued at $1,583,762. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Marion Mccourt sold 1,100 shares of the business’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $705.39, for a total value of $775,929.00. Following the transaction, the executive vice president now directly owns 19,644 shares of the company’s stock, valued at approximately $13,856,681.16. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 19,993 shares of company stock valued at $14,373,699. 8.99% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Trading Down 0.9 %

REGN opened at $734.45 on Friday. The company has a quick ratio of 4.52, a current ratio of 5.36 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $80.06 billion, a price-to-earnings ratio of 15.48, a P/E/G ratio of 2.16 and a beta of 0.20. Regeneron Pharmaceuticals, Inc. has a twelve month low of $538.01 and a twelve month high of $769.63. The company has a 50-day simple moving average of $715.16 and a 200 day simple moving average of $650.68.

Wall Street Analyst Weigh In

REGN has been the topic of several research reports. Raymond James downgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “underperform” rating in a report on Wednesday, October 26th. Cowen upped their price objective on shares of Regeneron Pharmaceuticals from $655.00 to $750.00 and gave the company a “market perform” rating in a report on Thursday, October 20th. Truist Financial upped their price objective on shares of Regeneron Pharmaceuticals from $790.00 to $856.00 in a report on Wednesday. Barclays boosted their target price on shares of Regeneron Pharmaceuticals from $735.00 to $815.00 and gave the company an “overweight” rating in a research report on Friday, September 9th. Finally, Wells Fargo & Company boosted their target price on shares of Regeneron Pharmaceuticals from $735.00 to $800.00 and gave the company an “overweight” rating in a research report on Monday, September 12th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $766.81.

Regeneron Pharmaceuticals Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Further Reading

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.